The global leukapheresis products market is projected to reach USD 27.7 million by 2023 from USD 19.4 million in 2018, at a CAGR of 7.4%.
Leukapheresis involves the separation of white blood cells from whole blood. Leukopaks are enriched leukapheresis products that contain higher concentrations of leukocytes. Leukopaks are regularly used in research settings and in cell therapy process development. The global leukopaks market is projected to reach USD 445.6 million by 2023, at a CAGR of 46.4%.
Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=20283148
Market growth can be attributed to the increasing incidence and prevalence of leukemia, growing demand for leukopaks for research applications, and increasing blood donations. However, the high cost of therapeutic leukapheresis and leukopaks, stringent donor recruitment criteria, the dearth of skilled professionals, and complications associated with therapeutic leukapheresis can hinder the growth of this market.
In this report, the global leukapheresis products market is segmented by type, application, end user, and region. By type, the global leukapheresis products market is segmented into leukapheresis devices and disposables. The leukapheresis devices segment is expected to register the highest CAGR during the forecast period. The growth of this segment can be attributed to the increasing number of therapeutic leukapheresis procedures conducted for the treatment of leukemia, immune-mediated inflammatory diseases, and inflammatory bowel disease.
On the basis of applications, the leukapheresis products market is segmented into research applications and therapeutic applications. The research application segment accounted for the fastest growth in the leukapheresis products market during the forecast period. The growth of this segment can be attributed to increasing adoption of leukapheresis for the isolation of WBCs for research applications such as the development of cell-based immunotherapies.
Based on end user, the leukapheresis products market is segmented into blood component providers & blood centers, hospitals & transfusion centers, academic & research institutes, and pharmaceutical & biotechnology companies. A surge in cell-based research, increasing research investment in the field of cancer immunotherapy, and increasing industry-academic partnerships and collaborations are some of the factors driving the growth of academic & research institutes market segment.
The global leukopaks market is segmented on the basis of type, indication, end user, and region. By type, the global leukopaks market is segmented into mobilized PB leukopaks, non-mobilized PB leukopaks, diseased leukopaks, and isolated PBMCs. The isolated PBMCs segment is expected to register the highest CAGR during the forecast period. The high growth of this segment can be attributed to the increasing use of primary cells such as T-cells, B-cells, Dendritic cells (DCs), and NK cells for the development of cell-based immunotherapies, such as CAR-T immunotherapy, NK cell-based therapy, and dendritic cell-based immunotherapy.
On the basis of indications, the leukopaks market is segmented into acute lymphocytic leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, hepatocellular carcinoma, pancreatic cancer, and other indications. The pancreatic cancer segment is expected to register the highest CAGR during the forecast period. The high growth of the segment can be attributed to the increasing research focus on the development of CAR-T Therapy for pancreatic cancer treatment.
Geographically, the leukapheresis market in the APAC region is expected to register the highest CAGR during the forecast period. Several APAC countries are witnessing a growing number of cell research activities; increasing research funding; increasing investments by pharmaceutical and biotechnology companies; and the growing trend of research infrastructure modernization. The rising geriatric population, growing per capita income, and increasing investments in the healthcare industry by key market players in the APAC region are the other key factors supporting the growth of the overall leukapheresis market in this region.
